Discordance Between Cobas BRAF V600 Testing and VE1 Immunohistochemistry in a Melanoma Patient With Bone Marrow Metastases
- 1 September 2016
- journal article
- case report
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
- Vol. 38 (9) , 687-689
Abstract
False negative result remains an ongoing problem in direct gene sequencing of cancers. It is important to use the appropriate mutation detection method most appropriate to each circumstance and the available tissue. Here, we report a patient with melanoma of unknown primary with metastases to spleen and bone marrow, who was tested negative for Cobas BRAF V600E mutation, whose cancer progressed on antiprogrammed death 1 (PD1) receptor monoclonal antibody therapy. Subsequent VE1 immunohistochemistry was positive for BRAF V600E mutation, and the tumor responded dramatically to v-Raf murine sarcoma viral oncogene homolog B (BRAF)/Mitogen-activated protein kinase inhibitor combination therapy. This demonstrates how alternative BRAF testing methodology could produce results that can influence treatment choice and the outcome.Keywords
This publication has 13 references indexed in Scilit:
- Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF InhibitorsClinical Chemistry, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyThe Lancet Oncology, 2014
- Improved Survival with MEK Inhibition in BRAF-Mutated MelanomaNew England Journal of Medicine, 2012
- Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastasesActa Neuropathologica, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Detection and quantification of mutations in the plasma of patients with colorectal tumorsProceedings of the National Academy of Sciences, 2005
- Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variationsProceedings of the National Academy of Sciences, 2003
- Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products: Figure 1Molecular Pathology, 2000